Reduced intravenous glutathione in the treatment of early Parkinson's disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 20, Issue 7, 1996, Pages 1159-1170

  Sechi, Gianpietro ^a,b   Deledda, Maria G ^a   Bua, Guido ^a   Satta, Wanda M ^a   Deiana, Giovanni A ^a   Pes, Giovanni M ^a   Rosati, Giulio ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b Neurological Clinic   (Italy)

Author keywords

Parkinson's disease; reduced glutathione

Indexed keywords

CARBIDOPA; GLUTATHIONE; LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE;

AGED; DISEASE PROGRESSION; FEMALE; GLUTATHIONE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; TREMOR;

EID: 0030273666     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(96)00103-0     Document Type: Article

References (21)

1. CORNFORD, E.M., BRAUN, L.D., CRANE, P.D. and OLDENDORF, W.H. (1978). Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 103: 1297-1303.
2. EHRINGER, H. and HORNYKIEWICZ, O.(1960). Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gemirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidalen Systems. Klin Wochenschr. 38 : 1236-1239.
3. GUY, W.(1976). (Ed). ECDEU assessment manual for psychopharmacology. Revised ed. Bethesda, MD : U.S. Department of Health, Education and Welfare.
4. HARIK, S.I. and MCGUNIGAL, T.(1984). The protective influence of the locus coeruleus on the blood-brain barrier. Ann Neurol 15 : 568-574.
5. JENNER, P.(1993). Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 87: Suppl. 146: 6-13.
6. JENNER, P., SCHAPIRA, A.H.W., and MARSDEN, C.D. (1992). New insights into the cause of Parkinson's disease. Neurology 42: 2241-2250.
7. MCNEIL, T.H., KOEK, L.L., HAYCOCK, J.W. and GASH, D.M.(1986). Glutathione depletion mimics MPTP neurotoxicity and age-correlated changes in dopamine neurons in substantia nigra of the C 57BL/6NNia mouse. Soc for Neuroscience Abstracts 12.
8. MEISTER, A. and TATE, S.S.(1976). Glutathione and related gamma-glutamyl compounds: biosynthesis and utilization. Ann Rev Biochem 45: 559-604.
9. MYLLYLA, V.V., SOTANIEMI, K.A., VUORINEN, J.A. and HEINONEN, E.M.(1992). Selegine as initial treatment in de novo parkinsonian patients. Neurology 42: 339-343.
10. PARDRIDGE, W.M.(1986). Blood-brain barrier: interface between internal medicine and brain. Ann Inter Med 105: 82-95.
11. PERRY, T.L, GODIN, D.V. and HANSEN, S.(1982). Parkinson's disease: a disorder due to a nigral glutathione deficiency. Neurosci Lett 33: 305-310.
12. RIEDERER, P., SOFIC, E., RAUSH, W.D., SHMIDT, B., REYNOLDS, G.P., JELLINGER. K. and YOUDIM, M.B.(1989). Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520.
13. SIAN, J., DEXTER, D.T., MARSDEN, C.D. and JENNER, P.(1992). Glutathione levels in brain neurodegenerative diseases affecting basal ganglia. Br J Pharmacol 106: 118 P.
14. SIAN, J., DEXTER, D.T., LEES, A.J., DANIEL, S., AGID, Y., JAVOY-AGID, F., JENNER, P. and MARSDEN, C.D.(1994). Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355.
15. TEYCHENNE, P.F., BERGSRUD, D., RACY, A., ELTON, R.L and VERN, B.(1982). Bromocriptine : low-dose therapy in Parkinson's disease. Neurology (Ny) 32: 577-583.
16. TOMONAGA, M.(1983). Neuropathology of the locus coeruleus: a semiquantitative study. J Neurol 230: 231-240.
17. TOOYAMA, I., KAWAMATA, T., WALKER, D., YAMADA, T., HANAI, K., KIMURA, H., IWANE, M., IGARASHII K., MCGEER, E.G. and MCGEER PL.(1993). Loss of basic fibroblast growth factor in substantia nigra neurons in parkinson's disease. Neurology 43 : 372-376.
18. VOLTERRA, A., TROTTI, D., TROMBA, C., FLORIDI, S. and RACAGNI, G.(1994). Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes J Neurosci 14 : 2924-2932.
19. WEBSTER, D.D.(1968) Critical analysis of disability in Parkinson's disease. Modern Treatment 5: 257-282.
20. YAHR, M.D., DUVOISIN, R.C., SCHEAR, M.J., BARRET and R.E. HOEHN, M.M. (1969). Treatment of parkinsonism with levodopa. Arch Neurol 21;343-354.
21. ZLOKOVIC, B.V., MACKIC, J.B., MC COMB, J.G., WEISS, M.H., KAPLOWITZ, N. and KANNAN, R.(1994). Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 201 : 402-408.